<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sinus bradycardia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sinus bradycardia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sinus bradycardia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Munther K Homoud, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Piccini, MD, MHS, FACC, FAHA, FHRS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sinus bradycardia is a rhythm in which the rate of impulses arising from the sinoatrial (SA) node is lower than expected.</p><p>The normal adult heart rate, arising from the SA node, has been considered historically to range from 60 to 100 beats per minute, with sinus bradycardia being defined as a sinus rhythm with a rate below 60 beats per minute. The heart rate reflects a complex interplay between the sympathetic and parasympathetic nervous systems. It is affected by numerous factors, including age and physical conditioning  (<a class="graphic graphic_table graphicRef77746" href="/z/d/graphic/77746.html" rel="external">table 1</a>) [<a href="#rid1">1,2</a>]. Sinus arrhythmia, the fluctuation in sinus rate with respiratory cycles, often accompanies sinus bradycardia. (See  <a class="medical medical_review" href="/z/d/html/1073.html" rel="external">"Normal sinus rhythm and sinus arrhythmia"</a>.)</p><p>The etiology, clinical presentation, evaluation, and management of sinus bradycardia will be reviewed here. Primary sinus node dysfunction (ie, sinus node dysfunction) is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/940.html" rel="external">"Sinus node dysfunction: Epidemiology, etiology, and natural history"</a> and  <a class="medical medical_review" href="/z/d/html/896.html" rel="external">"Sinus node dysfunction: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/1072.html" rel="external">"Sinus node dysfunction: Treatment"</a>.)</p><p class="headingAnchor" id="H1042741614"><span class="h1">DEFINITION AND ECG FEATURES</span><span class="headingEndMark"> — </span>Normal sinus rhythm (NSR) is the characteristic rhythm of the healthy heart. NSR is considered to be present in adults if the heart rate is between 60 and 100 beats per minute, the P wave vector on the electrocardiogram (ECG) is normal (ie, consistent with SA nodal impulse origin), and the rate is largely regular  (<a class="graphic graphic_waveform graphicRef58149" href="/z/d/graphic/58149.html" rel="external">waveform 1</a>). The normal sinus P wave demonstrates right atrial followed by left atrial depolarization and high to low atrial activation giving rise to an upright P wave in leads I, II, and aVL, and a negative P wave in lead aVR.</p><p>By conventional definition, bradycardia indicates a heart rate less than 60 beats per minute with a normal P wave vector on the surface ECG. As such, sinus bradycardia is typically thought of as sinus rhythm occurring at a rate of less than 60 beats per minute, although one professional society has advocated a rate of less than 50 beats per minute  (<a class="graphic graphic_waveform graphicRef52675" href="/z/d/graphic/52675.html" rel="external">waveform 2</a>) [<a href="#rid3">3</a>]. A rate less than 50 beats per minute may be a more pragmatic definition, as most patients with sinus rates in the 50s are asymptomatic. It is important to note that the rate at which a patient is labeled as having bradycardia is somewhat age dependent.</p><p class="headingAnchor" id="H1042741709"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Sinus bradycardia occurs in healthy patients as an adaptive response, particularly in well-conditioned persons or while sleeping, but it can also occur as a pathologic response in a variety of conditions.</p><p>It is very important to recognize that in normal healthy children and adults, sinus bradycardia is a frequent and normal finding, particularly during sleep when rates may transiently drop as low as 30 beats per minute, and pauses of up to two seconds are not uncommon [<a href="#rid4">4-7</a>]. Sinus bradycardia may also be seen in the absence of heart disease in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Well-conditioned athletes, particularly in endurance athletic activities, where bradycardia is generally attributed to increased vagal tone induced by exercise conditioning [<a href="#rid8">8-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some older adult patients, although this may represent an early manifestation of sinus node dysfunction (SND) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinus bradycardia may represent a manifestation of rare familial forms of SND that have been described. Mutations in two genes, HCN4 and SCN5A, have been associated with sinoatrial (SA) node dysfunction as well as other hereditary arrhythmic disorders such as the Brugada syndrome, atrial fibrillation, and progressive cardiac conduction disease [<a href="#rid14">14-16</a>].</p><p></p><p>Sinus bradycardia can be seen in a variety of pathophysiologic settings  (<a class="graphic graphic_table graphicRef65521" href="/z/d/graphic/65521.html" rel="external">table 2</a>), including:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sinus node dysfunction</strong> – Sinus bradycardia may be the first manifestation of SA node dysfunction [<a href="#rid17">17,18</a>]. Primary disease of the SA node is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/896.html" rel="external">"Sinus node dysfunction: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – A number of drugs can depress the SA node and slow the heart rate as either an expected response to or side effect of therapy, or as a toxicity related to overdose. These include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parasympathomimetic agents (eg, acetylcholine, <a class="drug drug_general" data-topicid="9197" href="/z/d/drug information/9197.html" rel="external">carbachol</a>, acetylcholinesterase inhibitors)</p><p class="bulletIndent2"><span class="glyph">•</span>Sympatholytic drugs (eg, beta blockers, <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">methyldopa</a>, <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">clonidine</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Opioids and sedatives</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">Cimetidine</a></p><p class="bulletIndent2"><span class="glyph">•</span>Digitalis</p><p class="bulletIndent2"><span class="glyph">•</span>Non-dihydropyridine calcium channel blockers (<a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">Ivabradine</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> and other antiarrhythmic drugs</p><p class="bulletIndent2"><span class="glyph">•</span>The chronic hepatitis C drugs <a class="drug drug_general" data-topicid="91794" href="/z/d/drug information/91794.html" rel="external">sofosbuvir</a> and daclatasvir in patients receiving <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> [<a href="#rid19">19</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a></p><p class="bulletIndent2"><span class="glyph">•</span>Chemotherapeutic agents (eg, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Organophosphate compounds [<a href="#rid20">20</a>]</p><p></p><p>A 2020 scientific statement from the American Heart Association details drugs associated with bradycardia [<a href="#rid21">21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute myocardial infarction</strong> – Sinus bradycardia occurs in 15 to 25 percent of patients with acute myocardial infarction, particularly those involving the right coronary artery as it supplies the SA node in approximately 60 percent of people. Increased vagal activity is primarily responsible, and the bradycardia is typically transient. If treatment is necessary because of hemodynamic compromise or ischemia, sinus bradycardia usually responds well to intravenous <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> (0.6 to 1.0 mg in the majority of cases). (See  <a class="medical medical_review" href="/z/d/html/82.html" rel="external">"Supraventricular arrhythmias after myocardial infarction", section on 'Sinus bradycardia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstructive sleep apnea</strong> – Individuals with obstructive sleep apnea frequently have sinus bradycardia that may be severe (&lt;30 beats per minute) during apneic episodes [<a href="#rid22">22</a>]. Therapies to improve the apnea frequently alleviate the bradycardia [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/7705.html" rel="external">"Obstructive sleep apnea and cardiovascular disease in adults", section on 'Other arrhythmias'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exaggerated vagal activity</strong> – Vasovagal responses may be associated with a profound bradycardia due to heightened parasympathetic activity and sympathetic withdrawal on the SA node. There are a variety of stimuli for vagal activation, including carotid sinus stimulation, vomiting, coughing, and Valsalva maneuver. The combination of the slow heart rate and an associated decline in peripheral vascular resistance is often sufficient to produce presyncope or syncope. (See  <a class="medical medical_review" href="/z/d/html/1050.html" rel="external">"Reflex syncope in adults and adolescents: Clinical presentation and diagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increased intracranial pressure and other central nervous system conditions</strong> — Increased intracranial pressure should be excluded when sinus bradycardia occurs in a patient with neurologic dysfunction. Stroke is another neurological condition that can display sinus bradycardia. Sinus bradycardia is also seen with trauma to the cervical or thoracic spine where sympathetic denervation of the heart leaves an unopposed parasympathetic tone [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious causes</strong> – Infectious agents associated with relative sinus bradycardia include Lyme disease, Chagas disease, legionella, psittacosis, Q fever, typhoid fever, typhus, babesiosis, malaria, leptospirosis, yellow fever, dengue fever, viral hemorrhagic fevers, trichinosis, and Rocky Mountain Spotted fever [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other causes</strong> – Other causes of sinus bradycardia include hypothyroidism, anorexia nervosa, hypothermia, and severe prolonged hypoxia. Sinus bradycardia is also seen in the long QT syndrome and in the catecholaminergic polymorphic ventricular tachycardia syndrome, two forms of genetic channelopathies.</p><p></p><p class="headingAnchor" id="H12"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>In the vast majority of patients, sinus bradycardia itself does not directly cause symptoms, although a patient with comorbid conditions that might be exacerbated by reduced cardiac output (eg, angina, heart failure) may present with worsening symptoms related to the comorbidity.</p><p>Symptoms related to the slow heart rate itself can occur, including lightheadedness, presyncope or syncope, worsening of angina pectoris or heart failure, cognitive slowing, and exercise intolerance. Symptoms may be subtle, with many patients noting only fatigue, which is frequently ascribed to aging rather than bradycardia. There is no specific heart rate below which all patients develop symptoms, as cardiac output will vary depending upon the ability to increase stroke volume related to underlying conditioning or comorbidities.</p><p>Sinus bradycardia associated with pathology of the sinoatrial node is part of the sinus node dysfunction (SND). SND often does not respond appropriately to exercise (chronotropic incompetence), and fatigue or dyspnea on exertion may be the presenting feature. SND and chronotropic incompetence are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/940.html" rel="external">"Sinus node dysfunction: Epidemiology, etiology, and natural history"</a> and  <a class="medical medical_review" href="/z/d/html/1548.html" rel="external">"Prognostic features of stress testing in patients with known or suspected coronary disease", section on 'Heart rate response to exercise'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">EVALUATION</span></p><p class="headingAnchor" id="H2428291643"><span class="h2">Confirm sinus bradycardia</span><span class="headingEndMark"> — </span>Sinus bradycardia is generally confirmed by ECG after a slow pulse is identified on physical examination, with the diagnosis usually being easy to establish from the surface ECG. An upright P wave in leads I, II, and aVL, and a negative P wave in lead aVR, indicates a sinus origin of the bradycardia. It is vital to exclude other causes of bradyarrhythmias such as atrioventricular (AV) block.</p><p class="headingAnchor" id="H1042742288"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Sinus bradycardia should be distinguished from other bradyarrhythmias  (<a class="graphic graphic_table graphicRef50037" href="/z/d/graphic/50037.html" rel="external">table 3</a>) resulting in a reduced heart rate (ie, second- or third-degree AV block, junctional escape rhythm, ventricular escape rhythm). This is easily done by establishing the 1:1 relationship between P waves and QRS complexes on the surface ECG. Patients with more than one P wave for every QRS complex have second- or third-degree AV block, while patients with no discernible P waves will have an escape rhythm (either junctional or ventricular in origin).</p><p>The heart rate is often clinically assessed by detection of the pulse with a plethysmograph system, and conditions other than sinus bradycardia can cause a reduction in measured pulse rate (for example, ventricular bigeminy, in which the premature ventricular complex beats result in diminished pulse pressure, which may not be detected). In such cases of ineffective bigeminy, a falsely low heart rate can be recorded. Thus, it is important to always obtain an ECG when new or unexpected bradycardia is identified.</p><p class="headingAnchor" id="H1042742348"><span class="h2">Further evaluation</span><span class="headingEndMark"> — </span>For the majority of patients with sinus bradycardia, the underlying cause can usually be determined from history and physical examination alone. In addition to the measurement of a full set of vital signs, including temperature and pulse oximetry, important features to elicit in a history and examination include:</p><p class="bulletIndent1"><span class="glyph">●</span>Quantity of exercise performed and level of fitness</p><p class="bulletIndent1"><span class="glyph">●</span>Exposure to medications and toxins</p><p class="bulletIndent1"><span class="glyph">●</span>Signs of infectious exposure (eg, tick or insect bites) or other systemic conditions (eg, eating disorders, hypothyroidism)</p><p></p><p>The evaluation of a patient who presents with sinus bradycardia requires a comprehensive evaluation where the history is probably the most important component of the evaluation  (<a class="graphic graphic_algorithm graphicRef103718" href="/z/d/graphic/103718.html" rel="external">algorithm 1</a>). The aim of the initial evaluation is to establish the presence or absence of symptoms, and any evidence of hemodynamic compromise as a result of the bradycardia. This may include hypotension, chest discomfort, altered mental status, or shortness of breath. The presence of hemodynamic compromise demands immediate attention to the cause of the bradycardia and its amelioration.</p><p>Once hemodynamic compromise has been excluded, the clinician will have to exclude diseases, cardiovascular or other, associated with sinus bradycardia and, most importantly, drugs associated with sinus bradycardia  (<a class="graphic graphic_algorithm graphicRef103718" href="/z/d/graphic/103718.html" rel="external">algorithm 1</a>). The list of medications, cardiovascular and otherwise, that suppress the sinus node is extensive.</p><p>Symptoms may be subtle such as lightheadedness, unexplained falls, or exertional dyspnea due to chronotropic incompetence, or they may be pronounced such as syncope. These symptoms point to underlying sinus node disease, which may or may not be exacerbated by drugs that suppress the sinus node. Sinus bradycardia in a healthy, athletic individual requires no further evaluation or intervention. On the other hand, sinus bradycardia in an older individual may indicate sinus node dysfunction (SND) [<a href="#rid27">27</a>]. Sinus bradycardia may be associated with ischemic heart disease if the blood supply to the sinus node (right coronary artery or, in some patients, the left circumflex artery) is compromised. Patients with congestive heart failure have slower heart rates than their healthy counterparts [<a href="#rid28">28</a>]. Sinus bradycardia in an individual with a history of atrial fibrillation and/or conduction disease, especially if associated with a family history of sinoatrial node dysfunction, should raise the possibility of a hereditary form of SND [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H14"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>For asymptomatic patients with sinus bradycardia, treatment is neither indicated nor required. The following approach should be followed when symptoms occur  (<a class="graphic graphic_algorithm graphicRef103718" href="/z/d/graphic/103718.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with symptoms who have evidence of hemodynamic instability, we administer <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a> (1.0 mg intravenous [IV] push, which can be repeated every three to five minutes, if needed, to a total dose of 3 mg) [<a href="#rid29">29-31</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If symptoms do not improve following <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">atropine</a>, proceed with temporary cardiac pacing and/or IV <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">dopamine</a> or <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> infusion [<a href="#rid29">29-31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1005.html" rel="external">"Temporary cardiac pacing"</a> and  <a class="medical medical_review" href="/z/d/html/278.html" rel="external">"Advanced cardiac life support (ACLS) in adults", section on 'Bradycardia'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If beta adrenergic or calcium channel blocker overdose is suspected, administer IV <a class="drug drug_general" data-topicid="8493" href="/z/d/drug information/8493.html" rel="external">glucagon</a>. The glucagon dose is 3 to 10 mg IV bolus given over three to five minutes; the bolus may repeat once if no response (increase in heart rate). If there is a response to bolus glucagon therapy, start a continuous infusion at 3 to 5 mg per hour titrated according to response [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If symptoms improve, the patient should be monitored with continuous cardiac telemetry.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are hemodynamically stable, the following should be considered:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with signs or symptoms of acute myocardial ischemia or infarction should be treated accordingly. (See  <a class="medical medical_review" href="/z/d/html/68.html" rel="external">"Overview of the acute management of non-ST-elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/66.html" rel="external">"Overview of the acute management of ST-elevation myocardial infarction"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with evidence of another systemic condition associated with sinus bradycardia (eg, hypothyroidism, infection, etc) should be treated accordingly. (See  <a class="medical medical_review" href="/z/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7915.html" rel="external">"Lyme carditis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients in whom a medication is suspected to be causing the symptomatic bradycardia should have the medication withheld. If the medication is mandatory for the treatment of a comorbid condition (eg, beta blockers for severe angina), a permanent pacemaker may be required [<a href="#rid30">30</a>]. If the symptoms resolve and heart rate improves following the withdrawal of the suspected offending agent, no additional immediate treatment is required.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with no other evidence of a potential cause should be evaluated for SND. (See  <a class="medical medical_review" href="/z/d/html/896.html" rel="external">"Sinus node dysfunction: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p></p><p class="headingAnchor" id="H1042742472"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>There is no adverse prognostic significance to sinus bradycardia in otherwise healthy subjects. In subjects over the age of 40, for example, there is no adverse effect on longevity [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H17476865"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16936.html" rel="external">"Patient education: Bradycardia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4453165"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Sinus bradycardia, most commonly defined as sinus rhythm with a rate below 60 beats per minute  (<a class="graphic graphic_waveform graphicRef52675" href="/z/d/graphic/52675.html" rel="external">waveform 2</a>), occurs in normal children and adults, particularly during sleep or at rest, in well-conditioned athletes, and in some older adult patients. Sinus bradycardia can also be seen in a variety of pathophysiologic settings, most commonly due to medication effects/toxicities or primary sinoatrial disease  (<a class="graphic graphic_table graphicRef65521" href="/z/d/graphic/65521.html" rel="external">table 2</a>). (See <a class="local">'Definition and ECG features'</a> above and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – In the vast majority of patients, sinus bradycardia itself does not cause symptoms. However, a slow heart rate can cause symptoms such as fatigue, lightheadedness, and presyncope or syncope. Patients with comorbid conditions that might be exacerbated by reduced cardiac output (eg, angina, heart failure) may present with worsening symptoms related to the comorbidity. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– The aim of the initial evaluation is to establish the presence or absence of symptoms, and any evidence of hemodynamic compromise as a result of the bradycardia  (<a class="graphic graphic_algorithm graphicRef103718" href="/z/d/graphic/103718.html" rel="external">algorithm 1</a>). Once hemodynamic compromise has been excluded, the clinician will have to exclude diseases, cardiovascular or other, associated with sinus bradycardia and, most importantly, drugs associated with sinus bradycardia. (See <a class="local">'Further evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management </strong>– For asymptomatic patients with sinus bradycardia, treatment is neither indicated nor required. The approach to the treatment of patients with symptomatic sinus bradycardia is presented within the text and the adjoining algorithm  (<a class="graphic graphic_algorithm graphicRef103718" href="/z/d/graphic/103718.html" rel="external">algorithm 1</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – There is no adverse prognostic significance to asymptomatic sinus bradycardia in otherwise healthy subjects. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H108312598"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Leonard Ganz, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Spodick DH. Normal sinus heart rate: sinus tachycardia and sinus bradycardia redefined. Am Heart J 1992; 124:1119.</a></li><li><a class="nounderline abstract_t">Spodick DH, Raju P, Bishop RL, Rifkin RD. Operational definition of normal sinus heart rate. Am J Cardiol 1992; 69:1245.</a></li><li><a class="nounderline abstract_t">Kadish AH, Buxton AE, Kennedy HL, et al. ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography. A report of the ACC/AHA/ACP-ASIM Task Force on Clinical Competence (ACC/AHA Committee to Develop a Clinical Competence Statement on Electrocardiography and Ambulatory Electrocardiography). J Am Coll Cardiol 2001; 38:2091.</a></li><li><a class="nounderline abstract_t">Scott O, Williams GJ, Fiddler GI. Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years. Br Heart J 1980; 44:304.</a></li><li><a class="nounderline abstract_t">Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol 1977; 39:390.</a></li><li><a class="nounderline abstract_t">Bjerregaard P. Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age. Eur Heart J 1983; 4:44.</a></li><li><a class="nounderline abstract_t">Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour Holter recordings. Am J Cardiol 1985; 55:1005.</a></li><li><a class="nounderline abstract_t">Talan DA, Bauernfeind RA, Ashley WW, et al. Twenty-four hour continuous ECG recordings in long-distance runners. Chest 1982; 82:19.</a></li><li><a class="nounderline abstract_t">Abdon NJ, Landin K, Johansson BW. Athlete's bradycardia as an embolising disorder? Symptomatic arrhythmias in patients aged less than 50 years. Br Heart J 1984; 52:660.</a></li><li><a class="nounderline abstract_t">Balady GJ, Cadigan JB, Ryan TJ. Electrocardiogram of the athlete: an analysis of 289 professional football players. Am J Cardiol 1984; 53:1339.</a></li><li><a class="nounderline abstract_t">Northcote RJ, Canning GP, Ballantyne D. Electrocardiographic findings in male veteran endurance athletes. Br Heart J 1989; 61:155.</a></li><li><a class="nounderline abstract_t">Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.</a></li><li><a class="nounderline abstract_t">Agruss NS, Rosin EY, Adolph RJ, Fowler NO. Significance of chronic sinus bradycardia in elderly people. Circulation 1972; 46:924.</a></li><li><a class="nounderline abstract_t">Milanesi R, Baruscotti M, Gnecchi-Ruscone T, DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med 2006; 354:151.</a></li><li><a class="nounderline abstract_t">Ruan Y, Liu N, Priori SG. Sodium channel mutations and arrhythmias. Nat Rev Cardiol 2009; 6:337.</a></li><li><a class="nounderline abstract_t">Hao X, Zhang Y, Zhang X, et al. TGF-β1-mediated fibrosis and ion channel remodeling are key mechanisms in producing the sinus node dysfunction associated with SCN5A deficiency and aging. Circ Arrhythm Electrophysiol 2011; 4:397.</a></li><li><a class="nounderline abstract_t">Alpert MA, Flaker GC. Arrhythmias associated with sinus node dysfunction. Pathogenesis, recognition, and management. JAMA 1983; 250:2160.</a></li><li><a class="nounderline abstract_t">Eraut D, Shaw DB. Sinus bradycardia. Br Heart J 1971; 33:742.</a></li><li><a class="nounderline abstract_t">Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149:1378.</a></li><li><a class="nounderline abstract_t">Ludomirsky A, Klein HO, Sarelli P, et al. Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol 1982; 49:1654.</a></li><li><a class="nounderline abstract_t">Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation 2020; 142:e214.</a></li><li><a class="nounderline abstract_t">Caples SM, Rosen CL, Shen WK, et al. The scoring of cardiac events during sleep. J Clin Sleep Med 2007; 3:147.</a></li><li><a class="nounderline abstract_t">Becker H, Brandenburg U, Peter JH, Von Wichert P. Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure. Am J Respir Crit Care Med 1995; 151:215.</a></li><li><a class="nounderline abstract_t">Gilson GJ, Miller AC, Clevenger FW, Curet LB. Acute spinal cord injury and neurogenic shock in pregnancy. Obstet Gynecol Surv 1995; 50:556.</a></li><li><a class="nounderline abstract_t">Cunha BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect 2000; 6:633.</a></li><li><a class="nounderline abstract_t">Puljiz I, Beus A, Kuzman I, Seiwerth S. Electrocardiographic changes and myocarditis in trichinellosis: a retrospective study of 154 patients. Ann Trop Med Parasitol 2005; 99:403.</a></li><li><a class="nounderline abstract_t">Dobrzynski H, Boyett MR, Anderson RH. New insights into pacemaker activity: promoting understanding of sick sinus syndrome. Circulation 2007; 115:1921.</a></li><li><a class="nounderline abstract_t">Sanders P, Kistler PM, Morton JB, et al. Remodeling of sinus node function in patients with congestive heart failure: reduction in sinus node reserve. Circulation 2004; 110:897.</a></li><li><a class="nounderline abstract_t">Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S729.</a></li><li><a class="nounderline abstract_t">Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74:e51.</a></li><li class="breakAll">https://cpr.heart.org/-/media/CPR-Files/CPR-Guidelines-Files/Algorithms/AlgorithmACLS_Bradycardia_200612.pdf (Accessed on January 06, 2022).</li><li><a class="nounderline abstract_t">Tresch DD, Fleg JL. Unexplained sinus bradycardia: clinical significance and long-term prognosis in apparently healthy persons older than 40 years. Am J Cardiol 1986; 58:1009.</a></li></ol></div><div id="topicVersionRevision">Topic 1075 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1529897" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Normal sinus heart rate: sinus tachycardia and sinus bradycardia redefined.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1575201" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Operational definition of normal sinus heart rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11738321" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography. A report of the ACC/AHA/ACP-ASIM Task Force on Clinical Competence (ACC/AHA Committee to Develop a Clinical Competence Statement on Electrocardiography and Ambulatory Electrocardiography).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7426187" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Results of 24 hour ambulatory monitoring of electrocardiogram in 131 healthy boys aged 10 to 13 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/65912" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6339245" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3984858" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Significance of ventricular pauses of three seconds or more detected on twenty-four-hour Holter recordings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7083929" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Twenty-four hour continuous ECG recordings in long-distance runners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6508966" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Athlete's bradycardia as an embolising disorder? Symptomatic arrhythmias in patients aged less than 50 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6231851" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Electrocardiogram of the athlete: an analysis of 289 professional football players.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2923752" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Electrocardiographic findings in male veteran endurance athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9691102" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Screening for hypertrophic cardiomyopathy in young athletes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5081144" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Significance of chronic sinus bradycardia in elderly people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407510" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19377496" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Sodium channel mutations and arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21493874" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : TGF-β1-mediated fibrosis and ion channel remodeling are key mechanisms in producing the sinus node dysfunction associated with SCN5A deficiency and aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6620520" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Arrhythmias associated with sinus node dysfunction. Pathogenesis, recognition, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5115019" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Sinus bradycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26253303" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7081053" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32929996" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17557424" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The scoring of cardiac events during sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7812557" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566833" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Acute spinal cord injury and neurogenic shock in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11284920" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The diagnostic significance of relative bradycardia in infectious disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15949188" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Electrocardiographic changes and myocarditis in trichinellosis: a retrospective study of 154 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420362" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : New insights into pacemaker activity: promoting understanding of sick sinus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302799" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Remodeling of sinus node function in patients with congestive heart failure: reduction in sinus node reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956224" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30412709" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30412709" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3490781" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Unexplained sinus bradycardia: clinical significance and long-term prognosis in apparently healthy persons older than 40 years.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
